Pharming Group N.V. (PHAR)
9.93
-0.19 (-1.88%)
At close: Jan 14, 2025, 1:34 PM
9.93
0.00%
After-hours Jan 14, 2025, 01:34 PM EST
undefined% (undefined)
| Bid | 9.33 |
| Market Cap | 6.74B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.27 |
| PE Ratio (ttm) | -36.78 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 15.6 |
| Volume | 1,892 |
| Avg. Volume (20D) | 6,578 |
| Open | 9.77 |
| Previous Close | 10.12 |
| Day's Range | 9.39 - 9.93 |
| 52-Week Range | 6.65 - 13.20 |
| Beta | undefined |
About PHAR
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 23, 2020
Employees 382
Stock Exchange NASDAQ
Ticker Symbol PHAR
Website https://www.pharming.com
Analyst Forecast
According to 3 analyst ratings, the average rating for PHAR stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 202.11% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Pharming Group N.V. is scheduled to release its earnings on Mar 13, 2025,
before market opens.
Analysts project revenue of $76.67M, reflecting a -5.58% YoY shrinking and earnings per share of 0.01, making a -75.00% decrease YoY.
Analysts project revenue of $76.67M, reflecting a -5.58% YoY shrinking and earnings per share of 0.01, making a -75.00% decrease YoY.
1 month ago ·
Source
+6.99%
Pharming Group shares are trading higher after Jef...
Unlock content with
Pro Subscription
2 months ago ·
Source
-7.37%
Pharming Group shares are trading lower after the company reported worse-than-expected Q3 financial results.
